SOLICITATION NOTICE
B -- Molecular characteristics of HIV-related non-Hodgkin lymphomas
- Notice Date
- 8/30/2010
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100217-TG
- Archive Date
- 9/29/2010
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS 6068, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Radiation Epidemiology Branch (REB) plans to procure on a sole source basis the evaluation of molecular characteristics of HIV-related non-Hodgkin lymphomas (NHL) from University of Southern California, Health Sciences Campus, Los Angeles, CA 90089. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541990 and the business size standard is $7.0 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. Non-Hodgkin lymphomas are the second most common malignancy among individuals infected with human immunodeficiency virus (HIV) and represent an AIDS-defining condition. Among the non-Hodgkin lymphoma subtypes, patients with HIV-related NHL are disproportionately at risk for diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma, but risk is elevated compared with the general population for all NHL subtypes. A small subset of NHL in the immunocompetent setting is associated with Epstein-Barr virus infection. Although infection-driven cancers are likely to increase in the setting of immunosuppression, the proportion of HIV-related NHLs that also are associated with other viruses is not well-established. In addition, gene expression profiling has strongly suggested that molecularly distinct disease entities with divergent clinical behavior exist within the current diagnostic categories, but the molecular characteristics of HIV-related NHLs are not well-characterized. The National Cancer Institute therefore seeks to expand our understanding of the pathogenetic contribution of immunosuppression to lymphomagenesis by comparing molecular and viral characteristics of NHLs in HIV- and non-HIV-infected individuals. The University of Southern California (USC) has the largest Surveillance, Epidemiology, and End Results Residual Tissue Repository (SEER-RTR), which routinely stores residual pathology tissue along with clinical and demographic data for cancer cases registered in Los Angeles county. The USC SEER-RTR has recently completed the creation of a unique collection of formalin-fixed, paraffin-embedded tissues for NHLs diagnosed in HIV- and non-HIV-infected individuals. The contractor shall conduct the following molecular studies for 139 HIV positive samples and 452 HIV negative samples from the USC SEER-RTR collection: Immunostaining to confirm the subtype of NHL according to the 2008 World Health Organization; Immunohistochemistry to determine EBV detection, HHV-8 detection, and DLBCL cell of origin & prognostic factors; In situ hybridization for EBV detection; and FISH to determine Cytogenetic abnormalities. USC is the only known source to provide the population-based nature of the samples, quantity of the collection, availability of sufficient tumor tissues to conduct the molecular studies and a unique resource for studying lymphomagenesis in the setting of immunosuppression. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on September 14, 2010. For further information, please contact Terry Galloway, Contract Specialist via electronic mail at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100217-TG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100217-TG/listing.html)
- Record
- SN02260140-W 20100901/100830235104-ce514602fb6f3616fd365ac8025622a5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |